Multicellular living organisms and unmodified parts thereof and – Method of using a transgenic nonhuman animal in an in vivo...
Reexamination Certificate
2005-08-19
2009-02-17
Crouch, Deborah (Department: 1632)
Multicellular living organisms and unmodified parts thereof and
Method of using a transgenic nonhuman animal in an in vivo...
C800S010000, C800S018000, C800S022000, C800S025000
Reexamination Certificate
active
07491865
ABSTRACT:
Transgenic, non-human animal model of cancer, methods of making such animals and methods of using such animals to screen test compounds are provided.
REFERENCES:
patent: 2003/0049645 (2003-03-01), Mu et al.
patent: 2003/0175736 (2003-09-01), Chinnaiyan et al.
patent: 2004/0048255 (2004-03-01), Chan et al.
patent: 2004/0132156 (2004-07-01), Parry et al.
Cameron, E.R. Recent Advances in Transgenic Techology, Molec. Biotech. 1997, vol. 7, pp. 253-265.
Sigmund, C.D. Viewpoint: Are Studies in Genetically Altered Mice Out of Control. Arteroscler. Throm. Vasc. Biol. 2000, vol. 20, pp. 1425-1429.
Niemann, H. Transgenic Farm Animals Get Off the Ground. Transg. Res. 1998, vol. 7, pp. 73-75.
Smith. Gene Transfer in Higher Animals: Theoretical Considerations and Key Concepts. J. Biotech. 2002, vol. 99, pp. 1-22.
Montoliu. Gene Transfer Strategies in Animal Transgenesis. Cloning and Stem Cells. 2002, vol. 4, pp. 39-46.
Ristevski. Making Better Transgenic Models. Molecular Biotechnology, vol. 29, pp. 153-163.
Yeung et al. Predisposition to Renal Carcinoma in the Eker Rat is Determined by Germ-Line Mutation of the Tuberous Sclerosis 2 (TSC2) Gene. Proced. Natl. Acad. Sci. Nov. 1994, vol. 91, pp. 11413-11416.
Wu. Gene Targeting in Hemostasis. Hepsin. Frontiers in Bioscience. Feb. 1, 2001, vol. 6, pp. 1-17.
Su et al. Consequences of Expression of Hepsin in Murine Vascular Systems. Journal of Thrombosis and Haemostasis. 2003, vol. 1., Suppl. 1, abstract P1730, meeting Jul. 12-18, 2003.
Kawamura et al. Complete Nucleotide Sequence, Origin of Isoform and Functional Characterization of the Mouse Hepsin Gene. European J. Biochem. 1999, vol. 262, pp. 755-764.
Masumori et al. A Probasin-Large T Antigen Transgenic Mouse Line Develops Prostate Adenocarcinoma and Neuroendocrine Carcinoma with Metastatic Potential. Cancer Res., Mar. 1, 2001, vol. 61, pp. 2239-2249.
Kananen et al. Gonadal Tumorigenesis in Transgenic Mice Bearing the Mouse Inhibin Alpha-Subunit Promoter/Simian Virus T-Antigen Fusion Gene: Characterization of Ovarian Tumors and Establishment of Gonadotropin-Responsive Granulosa Cell Lines. Molecular Endocrinology. 1995, vol. 9, pp. 616-627.
Abate-Shen and Shen, “Molecular genetics of prostate cancer,”Genes Dev.,14:2410-2434 (2000).
Bernards and Weinberg, “A progression puzzle,”Nature,418:823 (2002).
Chen et al., “Hepsin and maspin are inversely expressed in laser capture microdissectioned prostate cancer,”J. Urol.,169:1316-1319 (2003).
Del Rosso et al., “Multiple pathways of cell invasion are regulated by multiple families of serine proteases,”Clin. Exp. Metastasis,19:193-207 (2002).
Dhanasekaran et al., “Delineation of prognostic biomarkers in prostate cancer,”Nature,412:822-826 (2001).
Ernst et al., “Decrease and gain of gene expression are equally discriminatory markers for prostate carcinoma: a gene expression analysis on total and microdissected prostate tissue,”Am. J. Pathol.,160:2169-2180 (2002).
Ihara et al., “Prometastatic effect ofN-acetylglucosaminyltransferase V is due to modification and stabilization of active matriptase by adding β1-6 GlcNAc branching,”J. Biol. Chem.,277:16960-16967 (2002).
Kasper et al., “Development, progression and androgen-dependence of prostate tumors in probasin-large T antigen transgenic mice: a model for prostate cancer,”Lab. Invest.,78:319-333 (1998).
Kazama et al., “Hepsin, a putative membrane-associated serine protease, activates human factor VII and initiates a pathway of blood coagulation on the cell surface leading to thrombin formation,”J. Biol. Chem.,J. Biol. Chem., 270:66-72 (1995).
Klezovitch, et al., “Hepsin promotes prostate cancer progression and metastasis,”Cancer Cell,6:185-195 (2004).
Lin et al., “Prostate-localized and androgen-regulated expression of the membrane-bound serine protease TMPRSS2,”Cancer Res.,59:4180-4184 (1999).
Luo et al., “Human prostate cancer and benign prostatic hyperplasia: Molecular dissection by gene expression profiling,”Cancer Res.,61:4683-4688 (2001).
Magee et al., “Expression profiling reveals hepsin overexpression in prostate cancer,”Cancer Res.,61:5692-5696 (2001).
Netzel-Arnett et al., “Membrane anchored serine proteases: a rapidly expanding group of cell surface proteolytic enzymes with potential roles in cancer,”Cancer Metastasis Rev.,22:237-258 (2003).
Orsulic, “An RCAS-TVA-based approach to designer mouse models,”Mamm. Genome.,13:543-547 (2002).
Robinson et al., “The basic biology of metastasis,”Cancer Treat Res.,118:1-21 (2004).
Srikantan et al., “Hepsininhibits cell growth/invasion in prostate cancer cells,”Cancer Res.,62:6812-6816 (2002).
Stamey et al., “Molecular genetic profiling of Gleason grade 4/5 prostate cancers compared to benign prostatic hyperplasia,”J. Urol.,166:2171-2177 (2001).
Stephan et al., “Hepsin is highly over expressed in and a new candidate for a prognostic indicator in prostate cancer,”J. Urol.,171:187-191 (2004).
Takeuchi et al., “Cellular localization of membrane-type serine protease 1 and identification of protease-activated receptor-2 and single-chain urokinase-type plasminogen activator as substrates,”J. Biol. Chem.,275:26333-26342 (2000).
Takeuchi et al., “Reverse biochemistry: Use of macromolecular protease inhibitors to dissect complex biological processes and identify a membrane-type serine protease in epithelial cancer and normal tissue,”Proc. Natl. Acad. Sci. USA,96:11054-11061 (1999).
Tanimoto et al., “Hepsin, a cell surface serine protease identified in hepatoma cells, is overexpressed in ovarian cancer,”Cancer Res.,57:2884-2887 (1997).
Wallrapp et al., “A novel transmembrane serine protease (TMPRSS3) overexpressed in pancreatic cancer,”Cancer Res.,60:2602-2606 (2000).
Welsh et al., “Analysis of gene expression identifies candidate markers and pharmacological targets in prostate cancer,”Cancer Res.,61:5974-5978 (2001).
Wu, “Type II transmembrane serine proteases,”Curr. Top Dev. Biol.,54:167-206 (2003).
Yan et al., “Corin, a mosaic transmembrane serine protease encoded by a novel cDNA from human heart,”J. Biol. Chem.,274:14926-14935 (1999).
Zhang et al., “A small composite probasin promoter confers high levels of prostate-specific gene expression through regulation by androgens and glucocorticoids in vitro and in vivo,”Endocrinology,141:4698-4710 (2000).
Chevillet John
Klezovitch Olga
Matusik Robert J.
Vasioukhin Valeri
Crouch Deborah
Fred Hutchinson Cancer Research Center
Townsend and Townsend / and Crew LLP
Vanderbilt University
LandOfFree
Mouse models of prostate cancer development and metastasis... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Mouse models of prostate cancer development and metastasis..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Mouse models of prostate cancer development and metastasis... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4088420